NEWS

2024.03.27

Press Release

Submission of Clinical Trial Protocol Notice for Corneal Endothelial Therapy Cell Therapy, “AE101”

ActualEyes Inc. is pleased to announce the submission of the Phase II clinical trial protocol for “AE101,” a cutting-edge therapy for the treatment of bullous keratopathy, to the Pharmaceuticals and Medical Devices Agency (PMDA). After PMDA’s 30-day investigation of the clinical trial protocol, we anticipate commencing the clinical trial.

2022.11.18

Press Releases

Announcement of Licensing by Japan Innovative Therapeutics, Inc. of Corneal Endothelium Therapeutic Agents

2022.08.08

Press Releases

Aiming at Early Commercialization of Regenerative Medicine for Corneal Endothelium Manufacturing of regenerative medical product candidate AE101 starting at J-TEC

2022.08.03

Press Releases

Announcement of Appointment of Outside Director

2022.06.30

Press Releases

Conclusion of Joint Development Agreement for Corneal Endothelial Regenerative Medicine Product AE-101, and Series B Funding through Third-Party Allocation of Shares

This website uses cookies for the purpose of operating our services and improving the user experience. For details, please refer to our privacy policy. By clicking on the “Agree” button or continuing to use our website, you will be regarded as having agreed to our use of cookies.